Literature DB >> 15205556

Biological role of pituitary estrogen receptors ERalpha and ERbeta on progesterone receptor expression and action and on gonadotropin and prolactin secretion in the rat.

José E Sánchez-Criado1, Juana Martín De Las Mulas, Carmina Bellido, Manuel Tena-Sempere, Rafaela Aguilar, Alfonso Blanco.   

Abstract

Estrogen (E) is a key regulator of the synthesis and secretion of pituitary reproductive hormones [luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin (PRL)]. Until recently, it was thought that all biological actions of E at the pituitary were manifested through a single E receptor (R). The pituitary, like many other reproductive tissues, expresses two isoforms of ER, alpha and beta, both activated by E. The relative contribution of alpha and beta forms in E regulatory actions is largely unknown. To this end, 2-week-old ovariectomized (OVX) rats were injected over 3 days with 25 microg estradiol benzoate (EB), 1.5 mg of propylpyrazole triol (PPT), a selective ERalpha agonist, 1.5 mg of the selective ERbeta agonist diarylpropionitrile (DPN) or a combination of PPT and DPN. Controls were injected with 0.2 ml oil. At 10:00 h on the day after treatment, trunk blood was collected to determine serum concentration of LH, FSH and PRL, and pituitaries were processed for RT-PCR analysis of total (A+B) progesterone receptor (PR) mRNA, immunocytochemistry of PR and incubation. Pituitaries from each of the five groups were incubated in DMEM, with or without 20 nM of the antiprogestin at the receptor ZK299, for 3 h with: 10(-8)M 17beta-estradiol, 10(-6)M PPT, 10(-6)M DPN, PPT+DPN or medium alone, respectively, to determine LH, FSH and PRL secretion, and, when challenged with two pulses of 15 min 1 h apart of 10(-8)M gonadotropin-releasing hormone (GnRH) (GnRH self-priming). EB, PPT and PPT+DPN treatments increased PR mRNA and the number and intensity of nuclei immunoreactive (IR) for PR in gonadotropes, and reduced the number of gonadectomy cells. Like E, PPT alone or in combination with DPN stimulated PRL secretion, increased basal and GnRH-stimulated LH and FSH secretion and induced GnRH self-priming in the absence of ZK299 in the incubation medium. DPN alone had only a significant E-like effect on gonadectomy cells and IR-PR, but not on GnRH self-priming. In addition, while DPN lacked an agonistic action on peripheral tissue and serum pituitary reproductive hormones concentration, EB, PPT and PPT+DPN induced similar uterine ballooning and vaginal cornification, and increased and decreased, respectively, serum concentrations of PRL and gonadotropins. Overall, these results indicate that most of these E actions on the pituitary are exerted through the ERalpha isoform. The finding that activation of ERbeta with its selective DPN agonist had an estrogenic effect on IR-PR nuclei, but not on GnRH self-priming, a characteristic ERalpha-mediated effect of E, suggests that the biological action of E at the pituitary may involve both isoforms of ER.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205556     DOI: 10.1159/000079100

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  20 in total

1.  17β-oestradiol acts as a negative modulator of insulin-induced lactotroph cell proliferation through oestrogen receptor α, via nitric oxide/guanylyl cyclase/cGMP.

Authors:  S Gutiérrez; J P Petiti; L d V Sosa; L Fozzatti; A L De Paul; A M Masini-Repiso; A I Torres
Journal:  Cell Prolif       Date:  2010-10       Impact factor: 6.831

2.  Human follicular fluid from superovulated women inhibits progesterone receptor-dependent gonadotropin-releasing hormone self-priming in an estrous cycle-dependent manner in the rat.

Authors:  A Gordon; R Aguilar; J C Garrido-Gracia; C Bellido; Y Millán; S Guil-Luna; J A García-Velasco; E Bellido-Muñoz; J Martín de las Mulas; J E Sánchez-Criado
Journal:  J Endocrinol Invest       Date:  2010-05-17       Impact factor: 4.256

3.  Ovarian Androgens Maintain High GnRH Neuron Firing Rate in Adult Prenatally-Androgenized Female Mice.

Authors:  Eden A Dulka; Laura L Burger; Suzanne M Moenter
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

4.  The naturally occurring luteinizing hormone surge is diminished in mice lacking estrogen receptor Beta in the ovary.

Authors:  Friederike L Jayes; Katherine A Burns; Karina F Rodriguez; Grace E Kissling; Kenneth S Korach
Journal:  Biol Reprod       Date:  2014-02-06       Impact factor: 4.285

5.  Genistein inhibits proliferation and induces senescence in neonatal mouse pituitary gland explant cultures.

Authors:  Karen E Weis; Lori T Raetzman
Journal:  Toxicology       Date:  2019-10-05       Impact factor: 4.221

6.  The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes.

Authors:  James Bowe; Xiao Feng Li; James Kinsey-Jones; Arne Heyerick; Susan Brain; Stuart Milligan; Kevin O'Byrne
Journal:  J Endocrinol       Date:  2006-11       Impact factor: 4.286

7.  The response of creatine kinase specific activity in rat pituitary to estrogenic compounds and vitamin d less-calcemic analogs.

Authors:  D Somjen; N Mirsky; S Tamir; J Vaya; G H Posner; A M Kaye
Journal:  Int J Cell Biol       Date:  2009-09-10

8.  Estrogen regulation of gene expression in GnRH neurons.

Authors:  Yewade Ng; Andrew Wolfe; Horacio J Novaira; Sally Radovick
Journal:  Mol Cell Endocrinol       Date:  2009-02-02       Impact factor: 4.102

9.  Pituitary gonadotroph estrogen receptor-alpha is necessary for fertility in females.

Authors:  Mary C Gieske; Hyun Joon Kim; Sandra J Legan; Yongbum Koo; Andree Krust; Pierre Chambon; CheMyong Ko
Journal:  Endocrinology       Date:  2007-10-18       Impact factor: 4.736

10.  Differential expression of oestrogen receptor alpha following reproductive experience in young and middle-aged female rats.

Authors:  E M Byrnes; J A Babb; R S Bridges
Journal:  J Neuroendocrinol       Date:  2009-06       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.